{Reference Type}: Journal Article
{Title}: New horizons in aniridia management: Clinical insights and therapeutic advances.
{Author}: Gour A;Tibrewal S;Garg A;Vohra M;Ratna R;Sangwan VS;
{Journal}: Taiwan J Ophthalmol
{Volume}: 13
{Issue}: 4
{Year}: 2023 Oct-Dec
暂无{DOI}: 10.4103/tjo.TJO-D-23-00140
{Abstract}: Congenital aniridia is a rare genetic eye disorder characterized by the complete or partial absence of the iris from birth. Various theories and animal models have been proposed to understand and explain the pathogenesis of aniridia. In the majority of cases, aniridia is caused by a mutation in the PAX6 gene, which affects multiple structures within the eye. Treating these ocular complications is challenging and carries a high risk of side effects. However, emerging approaches for the treatment of aniridia-associated keratopathy, iris abnormalities, cataract abnormalities, and foveal hypoplasia show promise for improved outcomes. Genetic counseling plays a very important role to make informed choices. We also provide an overview of the newer diagnostic and therapeutic approaches such as next generation sequencing, gene therapy, in vivo silencing, and miRNA modulation.